HMGCL

Across TCGA pan-cancer cohorts, HMGCL mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of HMGCL’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HMGCL mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types HMGCL is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where HMGCL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HMGCL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−1.398	<.001	12	view →
COAD	Male	All	−0.325	<.001	9	view →
LSCC	Male	II,III,IV	−0.371	<.001	7	view →
HNSC	Male	II,III,IV	−0.311	<.001	7	view →
LUAD	Female	All	+0.303	<.001	4	view →
PDAC	Male	All	+0.422	<.001	3	view →
OV	All	All	+0.471	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

HMGCL–CCRCC

Open the CCRCC breakdown →